Sartorius CellGenix GmbH
CellGenix is a leading global supplier of high quality reagents and tools in the expanding markets of cell and gene therapy and regenerative medicine. CellGenix’ product portfolio includes growth factors, cytokines, serum-free media as well as closed cell culture systems (EU only). The products are used for the ex vivo cell processing in research, clinical applications and commercial production (e.g. DCs, T cells, NK cells, Stem cells, chondrocytes). The high quality of the products due to the state-of-the-art production, stringent in-house quality control and comprehensive documentation ensures a seamless transition from research to commerzialisation. As the first company to obtain a GMP manufacturing authorization for cell processing in Europe, CellGenix has more than 20 years of expertise in the development and GMP manufacturing of cell therapy products. The development and manufacturing takes place in Freiburg in accordance to relevant European and international guidelines (ISO, GMP, USP, PH.Eur.). The products are distributed worldwide either directly or through a wide distribution net. A subsidiary is located near Boston in Portsmouth, NH/USA.
- Founding: 1994
- Focus : Manufacturer
- Industry : Pharma
Products from CellGenix
News about CellGenix
05-Jul-2021 | Business
Sartorius acquires majority stake in CellGenix
The life science group Sartorius, through its subgroup Sartorius Stedim Biotech, has acquired a majority stake in the reagent manufacturer CellGenix GmbH. ...
18-Jul-2012 | Laws
CellGenix received ISO 9001:2008 certification
CellGenix’ quality management system was certified in April 2012 on the requirements of DIN EN ISO 9001:2008 standard by the TÜV Rheinland Cert GmbH. To ...
05-May-2009 | Business
CellGenix Technologie Transfer GmbH: 15 Years of Innovation and Leadership
2009 is a special year for CellGenix, according to the company. Cellgenix is celebrating its 15th anniversary. CellGenix was founded in May 1994 as a Spin- ...